1.1.1 Biologic drugs have been steadily gaining market share since the first biologic was approved by the U.S. Food and Drug Administration (FDA) in 1982. Historically, small molecule active pharmaceutical ingredients (APIs) held paramount significance within the global pharmaceutical industry, but they now represent only 69% of all new drugs approved by the FDA in the past decade (see Figure 1).[1] The trend continues through 2024. Two-thirds of 2024 new drug applications (NDAs) were for small molecules (Figure 2).[1]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.2.1 The pharmaceutical industry has been growing steadily and is expected to continue for the foreseeable future, and biologics are a growing subset of the industry. Within the space of biologics, antibodies have traditionally been the largest class of biologic drugs — in the pipeline and by sales of approved therapies. This trend is expected to continue, though antibody–drug conjugates (ADCs) are an especially fast-growing niche within the antibody market. ADC market growth is occurring across the entire development value chain. Each of these areas is discussed in depth in this report.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.3.1 The concept of a magic bullet — Zauberkugel — was first proposed by Nobel laureate Paul Ehrlich in 1907. The dream of developing a drug that will only injure the desired cells without harming healthy cells around it is finally becoming a reality. This reality takes the form of conjugating a toxic compound, the payload, to a monoclonal antibody. The road from Dr. Ehrlich’s 1907 proposal to today is a classic story of scientific progress in rapid leaps — and disappointing setbacks.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.4.1 Antibodies and ADCs have utility outside of therapeutics. Antibodies, often conjugated to some other entity, have long been used as critical research reagents for basic assays such as enzyme-linked immunosorbent assays (ELISAs), Western blots, flow blots, and flow cytometry.[10] Antibodies and ADCs are also becoming increasingly critical in imaging applications, such as immunoPET and biopsies.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.5.1 Most readers of this report are well aware that investor funding into biotech development has been through a roller coaster of record highs and alarming lows from 2020 to 2024. We previously discussed the cause, effect, and forecast of the overall market in other reports and content available on Pharma’s Almanac.[13]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.6.1 The pharmaceutical industry, once buoyed by the unprecedented demand and rapid innovation triggered by the COVID-19 pandemic, is currently readjusting to a post-COVID world, which has brought its own challenges, including a wave of layoffs that has swept across the biotech and pharma landscape in the past few years. This undercurrent of job reductions and corporate restructuring echoes the industry’s reflex to recalibrate in response to market pressures and strategic realignments, which appears at odds with forecasts of robust drug sales and potential market growth.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.